Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer

BACKGROUND: This economic analysis aimed to determine, from the perspective of a Canadian provincial government payer, the cost-effectiveness of docetaxel (Taxotere: Sanofi–Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide (tac) compared with 5-fluorouracil, doxorubicin, and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittmann, N., Verma, S., Koo, M., Alloul, K., Trudeau, M.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2010
Materias:
Practice Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826781/
https://www.ncbi.nlm.nih.gov/pubmed/20179798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826781/
https://www.ncbi.nlm.nih.gov/pubmed/20179798

Ejemplares similares